{"ATC Code":"N - Nervous system","Abbreviation":"","Aliases":["Eurodin","Julodin","Esilgan","D 40TA","Estazolamum","8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine","Abbott 47631","Abbott-47631","Estazolam civ","8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine"],"Biological Half-Life":"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.","CAS":"29975-16-4","ChEBI":"CHEBI:4858","ChEMBL":"CHEMBL285674","ChemicalClasses":["triazolobenzodiazepine"],"Chirality":"achiral","Classes":null,"DEA no":2756,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Benzodiazepines; Hypnotics and Sedatives","Drug Indication":"For the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.","DrugClasses":[],"EINECS":"249-982-4","EliminationHalfLife":"10 – 24 hours","Erowid Experience Reports":[],"European Community (EC) Number":"249-982-4","FDA Pharmacological Classification":"36S3EQV54C","HMDB ID":"HMDB0015346","HeavyAtomCount":21,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Benzodiazepines; Hypnotics and Sedatives","IUPACName":"8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine","Impurities":["2-(n-chloroacetyl-n-chloroacetylhydrazonomethyl)amino-5-chlorobenzophenone","(5-chloro-2-(3-ethyl-4h-1,2,4-triazol-4-yl)phenyl)phenylmethanone","5-chloro-2-(chloroacetamido)benzophenone","oxazepam benzophenone","(5-chloro-2-(3-(chloromethyl)-4h-1,2,4-triazol-4-yl)phenyl) phenyl ketone","nordazepam","5-chloro-2-formamidobenzophenone"],"InChI":"InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2","InChIKey":"CDCHDCWJMGXXRH-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)","Melting Point":"228-229","MolecularFormula":"C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e11\u003c/sub\u003eClN\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"294.74 g/mol","Pharmacodynamics":"Estazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.","Physical Description":"Solid","PrevSalts":[],"PubChemId":3261,"Record Description":["Estazolam is a triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia. It has a role as an anxiolytic drug, an anticonvulsant and a GABA modulator. It is a member of triazoles and a triazolobenzodiazepine.","Estazolam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.","Estazolam is a Benzodiazepine.","Estazolam is an orally available benzodiazepine used to treat insomnia. As with most benzodiazepines, estazolam has not been associated with serum aminotransferase or alkaline phosphatase elevations during therapy, and clinically apparent liver injury from estazolam has not been reported and must be very rare, if it occurs at all.","Estazolam is a triazolo-benzodiazepine with anxiolytic, anticonvulsant, hypnotic, and muscle relaxant properties. Estazolam binds to the gamma-aminobutyric acid (GABA) receptor at a site distinct from the inhibitory neurotransmitter GABA binding site in the limbic system of the central nervous system (CNS). This binding leads to an opening of the chloride channels, which allows the flow of chloride ions into the neuron, hyperpolarizes the neuronal membrane, inhibits neuronal firing, and leads to a decrease in neuronal excitability.","ESTAZOLAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for insomnia and has 1 investigational indication. This drug has a black box warning from the FDA.","Estazolam is only found in individuals that have used or taken this drug. It is a benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. [PubChem] Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA\u003csub\u003eA\u003c/sub\u003e) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.","A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.","Estazolam is a triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia. It has a role as an anxiolytic drug, an anticonvulsant and a GABA modulator. It is a member of triazoles and a triazolobenzodiazepine.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Estazolam","Name":"Estazolam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q3045264","Name":"Estazolam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01215","Name":"Estazolam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3261","Name":"Estazolam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL285674","Name":"Estazolam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4858","Name":"Estazolam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=29975-16-4","Name":"Estazolam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015346","Name":"Estazolam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C06981","Name":"Estazolam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/36S3EQV54C","Name":"Estazolam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5020572","Name":"Estazolam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3261, Estazolam. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3261\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3261\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Estazolam. UNII: 36S3EQV54C. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/36S3EQV54C\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/36S3EQV54C\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 26, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4","Scheduling":[{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class C substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"}],"Solubility":"Practically insoluble (1.5 mg/L)","StoreUNII":["36S3EQV54C"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="104.086mm" version="1.2" viewBox="0 0 82.067 104.086" width="82.067mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="105.0" stroke="none" width="83.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="78.292" x2="71.689" y1="41.29" y2="27.575"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="71.689" x2="77.363" y1="27.575" y2="18.18"/>
                        
                <line x1="70.517" x2="75.276" y1="24.799" y2="16.919"/>
                      
                <line class="hi" stroke="#3050F8" x1="77.363" x2="74.526" y1="18.18" y2="22.877499999999998"/>
                <line class="hi" stroke="#3050F8" x1="75.276" x2="72.8965" y1="16.919" y2="20.859"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="76.709" x2="72.448" y1="11.231" y2="6.31"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="66.361" x2="55.552" y1="4.374" y2="8.939"/>
                        
                <line x1="67.309" x2="58.133" y1="6.62" y2="10.496"/>
                      
                <line class="hi" stroke="#3050F8" x1="66.361" x2="60.956500000000005" y1="4.374" y2="6.656499999999999"/>
                <line class="hi" stroke="#3050F8" x1="67.309" x2="62.721000000000004" y1="6.62" y2="8.558"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="55.552" x2="56.526" y1="8.939" y2="20.276"/>
                  
            <line class="bond" id="mol1bnd6" x1="71.689" x2="60.161" y1="27.575" y2="24.891"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.824" x2="44.971" y1="26.557" y2="33.671"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="44.971" x2="44.971" y1="48.909" y2="33.671"/>
                        
                <line x1="42.532" x2="42.532" y1="47.501" y2="35.079"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="44.971" x2="31.764" y1="48.909" y2="56.528"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="18.557" x2="31.764" y1="48.909" y2="56.528"/>
                        
                <line x1="20.996" x2="31.764" y1="47.501" y2="53.713"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="18.557" x2="18.557" y1="48.909" y2="33.671"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="31.764" x2="18.557" y1="26.051" y2="33.671"/>
                        
                <line x1="31.764" x2="20.996" y1="28.866" y2="35.079"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="44.971" x2="31.764" y1="33.671" y2="26.051"/>
                  
            <line class="bond" id="mol1bnd14" x1="18.557" x2="6.875" y1="48.909" y2="55.656"/>
                  
            <line class="bond" id="mol1bnd15" x1="44.971" x2="56.857" y1="48.909" y2="58.458"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="56.857" x2="68.384" y1="58.458" y2="55.774"/>
                        
                <line x1="57.459" x2="67.831" y1="55.815" y2="53.399"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.384" x2="62.6205" y1="55.774" y2="57.116"/>
                <line class="hi" stroke="#3050F8" x1="67.831" x2="62.645" y1="53.399" y2="54.607"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="78.292" x2="73.476" y1="41.29" y2="51.293"/>
                  
            <line class="bond" id="mol1bnd18" x1="56.857" x2="53.471" y1="58.458" y2="73.316"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="64.656" x2="53.471" y1="83.679" y2="73.316"/>
                        
                <line x1="61.965" x2="52.846" y1="84.51" y2="76.061"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="64.656" x2="61.27" y1="83.679" y2="98.536"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="46.701" x2="61.27" y1="103.032" y2="98.536"/>
                        
                <line x1="47.327" x2="59.206" y1="100.287" y2="96.622"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="46.701" x2="35.517" y1="103.032" y2="92.669"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="38.902" x2="35.517" y1="77.811" y2="92.669"/>
                        
                <line x1="40.967" x2="38.207" y1="79.726" y2="91.837"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="53.471" x2="38.902" y1="73.316" y2="77.811"/>
                  
            <path class="atom" d="M81.507 16.981h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .733v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M71.532 5.459h-.721l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M58.797 26.571h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.055h.029q-.006 -.108 -.017 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M2.906 54.715q-.786 -.0 -1.239 .529q-.452 .524 -.452 1.447q-.0 .911 .417 1.447q.422 .53 1.268 .53q.321 -.0 .607 -.054q.291 -.06 .565 -.143v.536q-.274 .101 -.565 .149q-.292 .053 -.697 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q.0 -.744 .268 -1.31q.274 -.565 .804 -.881q.529 -.321 1.279 -.321q.78 -.0 1.352 .286l-.244 .524q-.226 -.102 -.506 -.185q-.274 -.083 -.607 -.083zM5.662 59.138h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M73.629 57.454h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .358 .023 .733v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.005 -.107 -.017 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm15" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="76.709" x2="74.57849999999999" y1="11.231" y2="8.7705"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="72.448" x2="74.57849999999999" y1="6.31" y2="8.7705"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="56.526" x2="56.039" y1="20.276" y2="14.6075"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="60.161" x2="65.925" y1="24.891" y2="26.232999999999997"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="53.824" x2="49.397499999999994" y1="26.557" y2="30.113999999999997"/>
            <line class="hi" id="mol1bnd14" stroke="#1FF01F" x1="6.875" x2="12.716" y1="55.656" y2="52.2825"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="73.476" x2="75.884" y1="51.293" y2="46.2915"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Estazolam","UNII":"36S3EQV54C","Wikidata":"Q3045264","Wikipedia":"Estazolam","XLogP":1.7}